L. M. Viranga Tillekeratne

L. M. Viranga Tillekeratne

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
RBRiddhidev Banerjee
Riddhidev Banerjee
Lalith PereraLalith Perera
Lalith Perera
LTL. M. Viranga Tillekeratne
L. M. Viranga Tillekeratne

30 October 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NKNishanth Kuganesan
Nishanth Kuganesan
SDSamkeliso Dlamini
Samkeliso Dlamini
LTL. M. Viranga Tillekeratne
L. M. Viranga Tillekeratne
WTWilliam Taylor
William Taylor
P53 is a well-established critical cell cycle regulator. By inducing transcription of the gene encoding p21, p53 inhibits cyclin-dependent kinase (CDK)-mediated phosphorylation of cell cycle inhibitor retinoblastoma (RB) proteins. Phosphorylation of RB releases E2F transcription factor proteins that transactivate cell cycle–promoting genes. Here, we sought to uncover the contribution of p53, p21, CDK, RB, and E2F to the regulation of ferroptosis, an oxidative form of cell death. Our studies have uncovered unexpected complexity in this regulation. First, we showed that elevated levels of p53 enhance ferroptosis in multiple inducible and isogenic systems. On the other hand, we found that p21 suppresses ferroptosis. Elevation of CDK activity also suppressed ferroptosis under conditions where p21 suppressed ferroptosis, suggesting that the impact of p21 must extend beyond CDK inhibition. Furthermore, we showed that overexpression of E2F suppresses ferroptosis in part via a p21-dependent mechanism, consistent with reports that this transcription factor can induce transcription of p21. Finally, deletion of RB genes enhanced ferroptosis. Taken together, these results show that signals affecting ferroptotic sensitivity emanate from multiple points within the p53 tumor suppressor pathway.

19 August 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EKEndri Karaj
Endri Karaj
SSShaimaa H. Sindi
Shaimaa H. Sindi
NKNishanth Kuganesan
Nishanth Kuganesan
Lalith PereraLalith Perera
Lalith Perera
WTWilliam Taylor
William Taylor
LTL. M. Viranga Tillekeratne
L. M. Viranga Tillekeratne

21 September 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PBPravin Bhansali
Pravin Bhansali
CHChristin L. Hanigan
Christin L. Hanigan
RJRobert A. Casero, Jr.
Robert A. Casero, Jr.
LTL. M. Viranga Tillekeratne
L. M. Viranga Tillekeratne

21 March 2022 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
EKEndri Karaj
Endri Karaj
SSShaimaa H. Sindi
Shaimaa H. Sindi
LTL. M. Viranga Tillekeratne
L. M. Viranga Tillekeratne

3 November 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JAJehad Almaliti
Jehad Almaliti
AAAyad A. Al-Hamashi
Ayad A. Al-Hamashi
ANAhmed Negmeldin
Ahmed Negmeldin
CHChristin L. Hanigan
Christin L. Hanigan
Lalith PereraLalith Perera
Lalith Perera
LTL. M. Viranga Tillekeratne
L. M. Viranga Tillekeratne